Neurotech International Ltd. has released a press release.
US FDA clears IND for NTI164
Earlier from Neurotech International
- NTI secures Notices of Allowance for US patent applications
- NTI initiates First Clinical Site for Phase 3 ASD Trial
- Appendix 4D & Half Year Report
- Positive 90-day GLP toxicology study results in non-rodents